Successful treatment of non-segmental vitiligo: systemic therapy with sex hormone-thyroid powder mixture.
We previously reported a patient with generalized vitiligo improved by oral administration of the drug for menopausal syndrome (sex hormone-thyroid powder mixture). In this study, we reevaluated the efficiency of this drug for vitiligo, and examined its pharmacological action in melanogenesis.
Nagai
K
K
Department of Dermatology and Biomolecular Recognition, Yamaguchi University School of Medicine, Ube, Japan.
Ichimiya
M
M
Yokoyama
K
K
Hamamoto
Y
Y
Muto
M
M
D000328:Adult; D000368:Aged; D015114:Androstenediol / Q000009:adverse effects / Q000627:therapeutic use*; D000735:Androstenedione / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004351:Drug Resistance; D004970:Estrone / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008544:Melanocytes / Q000378:metabolism; D008875:Middle Aged; D011284:Pregnenolone / Q000009:adverse effects / Q000627:therapeutic use*; D012727:Sex Characteristics; D012880:Skin Pigmentation; D013739:Testosterone / Q000009:adverse effects / Q000627:therapeutic use*; D013962:Thyroid (USP) / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014820:Vitiligo / Q000188:drug therapy* / Q000503:physiopathology; D000521:alpha-MSH / Q000378:metabolism
D004338:Drug Combinations; D013962:Thyroid (USP); D004970:Estrone; D013739:Testosterone; D000735:Androstenedione; D000521:alpha-MSH; D011284:Pregnenolone; C039452:Metharmon F; D015114:Androstenediol